Preclinical characterization of VX-984, a selective DNA-dependent protein kinase (DNA-PK) inhibitor in combination with doxorubicin in breast and ovarian cancers

被引:5
|
作者
Boucher, D. [1 ]
Newsome, D. [1 ]
Takemoto, D. [1 ]
Hillier, S. [1 ]
Wang, Y. [1 ]
Arimoto, R. [1 ]
Maxwell, J. [1 ]
Charifson, P. [1 ]
Fields, S. Z. [1 ]
Tanner, K. [1 ]
Penney, M. S. [1 ]
机构
[1] Vertex Pharmaceut Inc, Boston, MA USA
关键词
D O I
10.1158/1538-7445.SABCS16-P5-06-05
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
P5-06-05
引用
收藏
页数:1
相关论文
共 50 条
  • [1] Preclinical characterization of the selective DNA-dependent protein kinase (DNA-PK) inhibitor VX-984 in combination with chemotherapy
    Boucher, D.
    Hillier, S.
    Newsome, D.
    Wang, Y.
    Takemoto, D.
    Gu, Y.
    Markland, W.
    Hoover, R.
    Arimoto, R.
    Maxwell, J.
    Fields, S. Z.
    Charifson, P.
    Penney, M. S.
    Tanner, K.
    ANNALS OF ONCOLOGY, 2016, 27
  • [2] Discovery of VX-984: A novel, selective DNA-PK inhibitor for the treatment of cancer
    Maxwell, John
    Cottrell, Kevin
    Xu, Jinwang
    Arimoto, Rieko
    Boucher, Brian
    Chandupatla, Kishan
    Cochran, John
    Damagnez, Veronique
    Engtrakul, Juntyma
    Ford, Pamella
    Furey, Brinley
    Giroux, Simon
    Green, Jeremy
    Henry, Larry
    Hillier, Shawn
    Hogan, James
    Hoover, Russell
    Jackson, Katrina
    Markland, William
    Moody, Cameron
    Morris, Mark
    Pierce, Albert
    Shannon, Dean
    Stearns, Ralph
    Waal, Nathan
    Wang, Yuxin
    Wood, Mark
    Boucher, Diane
    Charifson, Paul
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2016, 251
  • [3] The DNA-PK Inhibitor VX-984 Enhances the Radiosensitivity of Glioblastoma Cells Grown In Vitro and as Orthotopic Xenografts
    Timme, Cindy R.
    Rath, Barbara H.
    O'Neill, Johnw.
    Camphausen, Kevin
    Tofilon, Philip J.
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (06) : 1207 - 1216
  • [4] Selective inhibition of the DNA-dependent protein kinase (DNA-PK) by the radiosensitizing agent caffeine
    Block, WD
    Merkle, D
    Meek, K
    Lees-Miller, SP
    NUCLEIC ACIDS RESEARCH, 2004, 32 (06) : 1967 - 1972
  • [5] Development of potent inhibitors of the DNA-dependent protein kinase (DNA-PK)
    Cano, Celine
    Bailey, Chris
    Bardos, Julia
    Curtin, Nicola
    Frigerio, Mark
    Golding, Bernard
    Hardcastle, Ian
    Hummersone, Marc
    Menear, Keith
    Newell, David
    Saravanan, Kappusamy
    Shea, K.
    Smith, Graeme
    Griffin, Roger
    CANCER RESEARCH, 2010, 70
  • [6] Development of potent inhibitors of the DNA-dependent protein kinase (DNA-PK)
    Cano, Celine
    Curtin, Nicola
    Hardcastle, Ian
    Golding, Bernard
    Smith, Graeme
    Newell, Herbie
    Griffin, Roger
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [7] Development of potent inhibitors of DNA-dependent protein kinase (DNA-PK)
    Barrett, Lauren
    Rennison, Tommy
    Clapham, Kate M.
    Rodriguez-Aristegui, Sonsoles
    Bardos, Julia
    Curtin, Nicola J.
    Dennis, M.
    Finlay, Ray
    Golding, Bernard T.
    Hardcastle, Ian R.
    Newell, David R.
    Young, Gail
    Cano, Celine
    Griffin, Roger J.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2013, 245
  • [8] Development of potent inhibitors of DNA-dependent protein kinase (DNA-PK)
    Clapham, K. M.
    Rennison, T.
    Rodriguez-Aristegui, S.
    Bardos, J.
    Curtin, N. J.
    Golding, B. T.
    Hardcastle, I. R.
    Newell, D. R.
    Cano, C.
    Griffin, R. J.
    EJC SUPPLEMENTS, 2010, 8 (07): : 140 - 140
  • [9] DNA-BINDING BY THE THE HUMAN DNA-DEPENDENT PROTEIN-KINASE, DNA-PK
    POLTORATSKY, V
    MALIK, N
    SAMSON, G
    LIEBER, M
    CARTER, T
    FASEB JOURNAL, 1995, 9 (06): : A1394 - A1394
  • [10] A novel, selective inhibitor of DNA-dependent protein kinase (DNA-PK) potentiates the effects of DNA-damaging therapies in hepatocellular carcinoma
    Willoughby, Catherine E.
    Thomas, Huw D.
    Rennison, Tommy
    Cano, Celine
    Reeves, Helen L.
    Wedge, Stephen R.
    CANCER RESEARCH, 2017, 77